MARK MATTA: Open Payments
NPI 1245424084 · NEW CASTLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$258,179 in 464 payments from 18 companies in 2025. Trend: 2023 $140,534 · 2024 $184,844 · 2025 $258,179
Speaker / faculty: $188,007Travel & lodging: $47,384Consulting: $12,386Food & beverage: $10,301Education: $101
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 67 | $70,799 |
| Vanda Pharmaceuticals Inc. | 101 | $70,600 |
| E.R. Squibb & Sons, L.L.C. | 48 | $34,544 |
| Teva Pharmaceuticals USA, Inc. | 48 | $28,008 |
| Otsuka America Pharmaceutical, Inc. | 47 | $26,363 |
| Alkermes, Inc. | 53 | $21,235 |
| ABBVIE INC. | 42 | $5,312 |
| Neurocrine BioSciences, Inc. | 13 | $470 |
| Janssen Pharmaceuticals, Inc | 12 | $227 |
| Corium, LLC | 7 | $114 |
Products named: CAPLYTA, FANAPT, COBENFY, REXULTI, LYBALVI, AUSTEDO XR, UZEDY, VRAYLAR.
Industry payments across PA — which companies pay providers there.
